以下文章来源于解码LP ，作者周佳丽 解码LP . 投资界（PEdaily.cn）旗下，专注募资动态 由两个500亿基金组成。 作者 I 周佳丽 报道 I 投资界-解码LP 上海继续放大招。 3月2 5日，2 0 2 5上海全球投资促进大会拉开帷幕。投资界-解码LP从现场获悉，上海产业转型升级二期基金、国资并购基金矩阵正式启 动，上海将通过这两只" 50 0亿"基金，更大力度支持实体经济发展。 形成3 0 0 0亿元并购交易规模，激活总资产超2万亿元； 集聚3—5家有较强行业影响力的专业并购基金管理人； 用好1 0 0亿元集成电路设计产业并购基金，设立1 0 0亿元生物医药产业 并购基金； 其中，上海将发展并购基金列入今年重点任务，新组建的国资并购基金矩阵总规模达到5 0 0亿元以上。想起去年底，上海刚刚发布《上 海市支持上市公司并购重组行动方案（2 0 2 5—2 0 2 7年）》，直到这一次组建总规模5 0 0亿元的国资并购基金矩阵，进一步吹响并购号 角。 目之所及，上海推动重大产业战略升级的决心不言而喻。 上海正式发布两大基金矩阵 总规模超1000亿 揭开面纱。 上海市产业转型升级二期基金总规模达5 0 ...

Core Insights - Solid Biosciences Inc. is set to present data from the Phase 1/2 INSPIRE DUCHENNE trial for SGT-003, a gene therapy for Duchenne muscular dystrophy, at the 2025 MDA Clinical & Scientific Conference [1] - Duchenne muscular dystrophy is a severe genetic disease affecting approximately 5,000 to 15,000 cases in the U.S., primarily in boys [2] - SGT-003 utilizes a differentiated microdystrophin construct and a next-generation capsid designed to enhance muscle transduction while minimizing liver targeting, indicating its potential as a leading gene therapy for Duchenne [3] - The INSPIRE DUCHENNE trial is a first-in-human, open-label study aimed at evaluating the safety and efficacy of SGT-003 in pediatric patients with confirmed Duchenne diagnosis [4] - Solid Biosciences focuses on developing gene therapies for rare neuromuscular and cardiac diseases, with a mission to improve the lives of patients affected by these conditions [5]

CHARLESTOWN, Mass., March 12, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, will present data from the Phase 1/2 INSPIRE DUCHENNE trial evaluating SGT-003, a next-generation gene therapy product candidate intended for the treatment of Duchenne muscular dystrophy (Duchenne), at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference, taking place in Dallas, TX, March ...

文/梧桐小编 3月6日下午，中国证监会主席吴清在在十四届全国人大三次会议经济主题记者会上回答记者提问。吴清指出：证监会始终高度重视支持科技创新，近年来我们以 科创板、创业板等系列改革为契机，深入推进关键制度创新，不断提升资本市场的"科技含量"。2024年，科创板、创业板、北交所新上市公司中高新技术企业占 比均超过9成，目前全市场战略性新兴产业上市公司市值占比已超过4成，先进制造、新能源、新一代信息技术、生物医药等重点领域涌现出一批龙头领军企业， 资本市场服务科技创新、产业创新的质效明显提升。加快健全专门针对科技企业的支持机制。坚持有效市场和有为政府相结合，聚焦科技创新活跃、体现新质生 产力方向的领域， 用好"绿色通道"、未盈利企业上市等制度，稳妥实施科创板第五套上市标准等更具包容性的发行上市制度，更精准支持优质科技企业发行上 市。 大力度培育长期资本、耐心资本。从全球经验看，很多引领性科技企业的崛起，离不开长期耐心的资本投入。只有耐得住"十年磨一剑"的寂寞，才能迎来"一 鸣惊人"的辉煌。 十四届全国人大三次会议于2025年3月6日（星期四）下午3时，在梅地亚中心新闻发布厅举行记者会。国家发展和改革委员会主任郑 ...

Core Insights - Solid Biosciences Inc. is advancing its gene therapy programs for neuromuscular and cardiac diseases, with significant clinical milestones expected in 2025 and beyond [3][5][6] Financial Overview - As of December 31, 2024, the company reported $148.9 million in cash, cash equivalents, and available-for-sale securities, an increase from $123.6 million in 2023 [2][18] - The company anticipates a cash runway into the first half of 2027, bolstered by $200 million in gross proceeds from a recent equity offering [2][18] Clinical Development Updates - Initial data from the Phase 1/2 INSPIRE DUCHENNE trial for SGT-003 showed promising safety and improvements in muscle integrity biomarkers, with plans for FDA discussions on accelerated approval pathways in mid-2025 [3][7][8] - SGT-212, targeting Friedreich's ataxia, received FDA IND clearance, with the first human trial expected to start in the second half of 2025 [5][7][10] Pipeline and Partnerships - The proprietary capsid AAV-SLB101 used in SGT-003 demonstrated robust transduction and expression levels, leading to potential partnerships with 19 academic and corporate entities [4][13] - The company is building a library of capsids and promoters for future gene therapy applications, with a focus on cardiac and neuromuscular diseases [12][13] Research and Development Expenses - R&D expenses for Q4 2024 were $30.8 million, up from $15.5 million in Q4 2023, with full-year R&D expenses totaling $96.4 million compared to $76.6 million in 2023 [18][21] - General and administrative expenses also increased, reflecting higher personnel costs, totaling $33.3 million for the full year 2024 [18][21] Net Loss - The net loss for Q4 2024 was $42.6 million, compared to $20.3 million in Q4 2023, with a full-year net loss of $124.7 million versus $96.0 million in 2023 [18][21]

Core Insights - Vericel (NASDAQ: VCEL) operates in the regenerative medicine sector, which is currently undervalued by the market [1] - The company has achieved steady revenue growth through FDA-approved products such as MACI, Epicel, and NexoBrid, contrasting with larger biotech firms focused on blockbuster drug approvals [1] Company Overview - Vericel has established a niche in regenerative medicine, differentiating itself from larger biotech companies [1] - The company’s revenue-generating products are recognized for their FDA approval, contributing to consistent revenue growth [1] Market Position - The market tends to overlook Vericel in favor of larger biotech names, despite its strong performance and growth potential [1] - The focus on high-growth companies in sectors with potential for exponential expansion aligns with Vericel's business model [1]

Core Viewpoint - Pluri Inc. has entered into an exclusive collaboration with Hemafund Ltd. to develop and distribute PLX-R18 cell therapy as a countermeasure against Hematopoietic Acute Radiation Syndrome (H-ARS) in Ukraine, in response to recent escalations in regional nuclear threats [1][3]. Group 1: Collaboration Agreement - The collaboration agreement is effective for an initial period of three years, with the possibility of a three-year extension [1]. - Pluri will produce and supply PLX-R18, while Hemafund will utilize its biostorage and logistics expertise to ensure compliance with local regulations [2][9]. - The collaboration aims to secure external funding to build an initial capacity of 12,000 doses of PLX-R18, sufficient to treat 6,000 individuals [4][5]. Group 2: Strategic Goals - The collaboration addresses Ukraine's urgent need for radiation countermeasures and ensures secure storage and rapid deployment of treatments [8]. - It seeks to attract public and private funding to support the development and accessibility of PLX-R18 [9]. - The collaboration may potentially generate over $100 million in value for both parties based on the estimated cost per dose and projected stockpile [5]. Group 3: Context and Need - The collaboration is a response to recent incidents, including a Russian drone strike on the Chernobyl nuclear power plant, highlighting the need for effective radiation countermeasures [3]. - H-ARS is caused by exposure to high levels of ionizing radiation, leading to severe health risks [6].

构建人工智能创新生态，助力上海构建人工智能创新策源地。 本文为IPO早知道原创 作者｜苏打 微信公众号｜ipozaozhidao 据IPO早知道消息，2024年12月30日，上海三大先导产业母基金首批遴选生态合作伙伴签约暨第二 批遴选申报发布仪式在上海举行。 现场， 上海国投公司与浦东新区共同发布上海具身智能基金、与徐汇区共同发布上海大模型基金， 旨在发掘人工智能领域相关科技创新项目，构建人工智能创新生态，助力上海构建人工智能创新策源 地 。 仪式上，三大先导产业母基金管理公司与首批12家生态合作基金正式签约，共认缴出资67亿，基金 总规模250亿，放大倍数3.73倍。市相关部门共同发布上海三大先导产业母基金第二批遴选申报， 彰显了上海市各相关部门在促进三大先导产业发展和创新升级方面的紧密协同和鼎力支持。 部分"上海国投"系基金管理人围绕三大先导产业生态圈建设，分别与相关生态合作伙伴签约，进一 步巩固产业链上下游的协同关系。生态合作基金代表包括启明创投、中科创星、礼来亚洲等。 为贯彻落实11月27日上海市与部分中央金融机构负责人座谈会精神，上海国投公司与新华保险、国 开行上海分行、国寿资产、中信证券等金融机构 ...